-
1 Comment
Celltrion Pharm Inc is currently in a long term uptrend where the price is trading 3.7% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Other sector with a price to sales ratio of 0.0.
Celltrion Pharm Inc's total revenue rose by 72.3% to $77B since the same quarter in the previous year.
Its net income has increased by 153.0% to $11B since the same quarter in the previous year.
Finally, its free cash flow grew by 11.4% to $6B since the same quarter in the previous year.
Based on the above factors, Celltrion Pharm Inc gets an overall score of 5/5.
| Industry | Other |
|---|---|
| Sector | Other |
| ISIN | KR7068760008 |
| CurrencyCode | KRW |
| Exchange | KO |
| PE Ratio | nan |
|---|---|
| Target Price | nan |
| Beta | nan |
| Dividend Yield | nan% |
| Market Cap | None |
None
Here's how to backtest a trading strategy or backtest a portfolio for 068760.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
